Skeletal and Soft Tissue Sarcomas: Treatment With Adjuvant Immunotherapy

Courtney M. Townsend, Frederick R. Eilber, Donald L. Morton

Research output: Contribution to journalArticle

15 Scopus citations

Abstract

Because there is evidence for an active immunologic response against sarcoma, a clinical trial of adjuvant immunotherapy using bacillus Calmette-Guérin (BCG) and tumor cell vaccine was begun. Eleven of 18 patients with localized soft tissue sarcoma who received immunotherapy are free of disease, compared to only 5 of 15 treated by operation alone who are free of disease. Furthermore, immunotherapy also prolonged the median disease-free interval from 7.3 months to 15 months in the patients who experienced recurrence of their disease.

Original languageEnglish (US)
Pages (from-to)2187-2189
Number of pages3
JournalJAMA: The Journal of the American Medical Association
Volume236
Issue number19
DOIs
StatePublished - Nov 8 1976

    Fingerprint

ASJC Scopus subject areas

  • Medicine(all)

Cite this